Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766141 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL11528188 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL29118750 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL2723206 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL9762896 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL15445144 | 1.00 | TSHR (0.52) | TSHRGAAMEN1KMT2ATHRB | |
| SCHEMBL2360071 | 0.98 | — | — | |
| SCHEMBL1142610 | 0.90 | — | — | |
| SCHEMBL2706386 | 0.90 | MEN1 (0.53) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL766061 | 0.87 | TSHR (0.56) | TSHRMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| US-12077555-B2 | STAT degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20150210781-A1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | NANTES UNIVERSITE (FR) | 2015-07-30 | — | — | US | disclosed |
| US-20150210781-A1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | NANTES UNIVERSITE (FR) | 2015-07-30 | — | — | US | disclosed |
| EP-0975586-B1 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6448444-B2 | INSECTICIDES, MITICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-09-10 | — | — | US | disclosed |
| US-6437184-B1 | INSECTICIDES, ACARICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-20 | — | — | US | disclosed |
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-02-14 | — | — | US | disclosed |
| EP-0975586-A2 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | Sumitomo Chemical Company, Limited (JP) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998045254-A2 | OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-10-15 | — | — | WO | disclosed |
| EP-0228222-A2 | Pesticidal dihalovinylalkenylamides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019569-A1 | Oxime compounds, their use, and intermediates for their production | CBR3, CBR1, NOX3 | TSHR 2061/4885GAA 3855/4885MEN1 4425/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885GAA 1234/4885MEN1 4055/4885 |
| US-12077555-B2 | STAT degraders and uses thereof | STAT4, STAT1, STAT3 | TSHR 1768/4885GAA 312/4885MEN1 3280/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885GAA 1234/4885MEN1 4055/4885 |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | TSHR 1768/4885GAA 312/4885MEN1 3280/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885GAA 1234/4885MEN1 4055/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885GAA 1234/4885MEN1 4055/4885 |
| US-20150210781-A1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | MANBA, MAN2A1, MAN2B2 | TSHR 4747/4885GAA 123/4885MEN1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.